A Case of B-Prolymphocytic Leukemia and Another Case of B-Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia.
- Author:
Seung Hyun LEE
1
;
Seuk Young CHOI
;
Tae Gyu PARK
;
Dong Hwa LEE
;
Hee Sik KIM
;
Jae Sung LEE
;
Chan Woo LEE
;
Seong Pok CHEONG
;
Kyung Hee LEE
;
Myung Soo HYUN
Author Information
1. Department of Internal Medicine, Pohang St. Mary's Hospital1, Pohang, Korea.
- Publication Type:Case Report
- Keywords:
Prolymphocytic leukemia;
Chronic lymphocytic leukemia;
Chronic lymphocytic leukemia/prolymphocytic leukemia
- MeSH:
B-Lymphocytes;
Chlorambucil;
Drug Therapy;
Hepatomegaly;
Humans;
Leukemia*;
Leukemia, Lymphocytic, Chronic, B-Cell;
Leukemia, Prolymphocytic;
Lymph Nodes;
Physical Examination;
Prednisolone;
Prognosis;
Splenomegaly
- From:Korean Journal of Hematology
1999;34(2):344-348
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Prolymphocytic leukemia (PL) is usually derived from B cells and shares some features with chronic lymphocytic leukemia (CLL), but it is clearly a distinct entity and defined to have more than 55% prolymphocytes. Chronic lymphocytic leukemia/prolymphocytic leukemia (CLL/PL) is a mixed type of CLL and is defined to have 11~55% prolymphocytes with intermediate features between CLL and PL. We experienced two different cases of leukemia PL and CLL/PL. On physical examination, PL (stage II, B) patient showed multiple cervical lymph node enlargement and 5cm sized splenomegaly and hepatomegaly. But CLL/PL (stage III, C) patient showed 10cm sized splenomegaly and no lymph node enlargement. On immunological phenotyping, surface markers showed 72% CD5 (+), 85% CD19 (+), and 40% SmIg (+) in PL patient and 3% CD5 (+), 90% CD19 (+) and SmIg (-) in CLL/PL patient. PL patient was refractory to chlorambucil and prednisolone chemotherapy and showed poor prognosis. CLL/PL patient did not show remarkable response to chlorambucil and prednisolone therapy.
